•Ovarian cancer is the most lethal among gynecological cancers.•Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients.•Almost one every three patients treated with carboplatin experiences hypersensitivity reactions.•Patients may experience breakthrough reactions during drug desensitization.•Omalizumab represents a promising new treatment to overcome carboplatin hypersensitivity.
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer / Vultaggio, Alessandra; Petrella, Maria Cristina; Tomao, Federica; Nencini, Francesca; Mecheri, Valentina; Marini, Andrea; Perlato, Margherita; Vivarelli, Emanuele; De Angelis, Claudia; Ferrarini, Ilaria; Pillozzi, Serena; Matucci, Andrea; Antonuzzo, Lorenzo. - In: GYNECOLOGIC ONCOLOGY REPORT. - ISSN 2352-5789. - STAMPA. - 38:(2021), pp. 100880.1-100880.4. [10.1016/j.gore.2021.100880]
The anti-IgE monoclonal antibody omalizumab as adjuvant treatment in desensitization to carboplatin in patients with ovarian cancer
Vultaggio, Alessandra;Petrella, Maria Cristina;Nencini, Francesca;Mecheri, Valentina;Marini, Andrea;Perlato, Margherita;Vivarelli, Emanuele;Pillozzi, Serena;Matucci, Andrea;Antonuzzo, Lorenzo
2021
Abstract
•Ovarian cancer is the most lethal among gynecological cancers.•Carboplatin-based chemotherapy identifies as the main systemic treatment for ovarian cancer patients.•Almost one every three patients treated with carboplatin experiences hypersensitivity reactions.•Patients may experience breakthrough reactions during drug desensitization.•Omalizumab represents a promising new treatment to overcome carboplatin hypersensitivity.
| File | Dimensione | Formato | |
|---|---|---|---|
|
main (2).pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
345.55 kB
Formato
Adobe PDF
|
345.55 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
